Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Viking Therapeutics arrives at its October 21 earnings date down 11% on the week and 19% on the month, carrying one of the heavier short books in biotech and a borrow market that has tightened sharply against a stock that the Street still prices at roughly three times its current level.
Short interest is the defining feature of this setup. At 21.1% of the free float, with around 23.9 million shares short, bears have a substantial position that has grown 7.4% over the past month even as the stock has sold off. That is the behaviour of shorts adding into weakness rather than covering into it. The ORTEX short score reinforces the picture, registering 73.8 out of 100, a reading that has held consistently above 73 for the past two weeks. Where the borrow market tells a more nuanced story is in availability: at 80.7% of short interest, there is still meaningful capacity for new shorts to enter. But the direction of travel matters. Availability stood above 200% through most of September. It has more than halved since then, compressing to 80.7% as the short book built. Cost to borrow, meanwhile, has doubled from its mid-September lows of around 0.28% to 0.77%, still inexpensive in absolute terms but rising fast enough to reflect the tightening pool. Options traders are not adding to the bearish signal: the put/call ratio of 0.24 is barely above its 20-day average and sits well off the 52-week high of 0.54, meaning the call side continues to dominate activity despite the price decline.
The gap between where the stock trades and where analysts think it belongs is striking, though it comes with caveats. The mean analyst price target is around $95, against a close of $28.38. That is more than a 3x gap, which typically suggests either stale targets or a market that has moved decisively past the consensus. The most recent move came today from Truist Securities, which trimmed its target modestly from $87 to $85 while keeping its Buy rating. That follows JP Morgan's cut in August from $75 to $65, also retaining Overweight. The direction of recent analyst revisions has been downward, but coverage remains constructively rated across the board. The bear case centres on Ligand's April termination of the THR-beta licence agreement, which creates legal and commercialization uncertainty for VK2809 and VK0214 and removes milestone and royalty economics that were part of the original pipeline thesis. The bull case rests on the VK2735 maintenance data: 21.7% weight loss at week 33 in the continued-weekly cohort and retention of 97%, with no apparent plateau suggesting the Phase 3 VANQUISH doses have meaningful headroom. The $603 million cash balance provides runway into 2028, which limits near-term financing risk even as quarterly R&D spend runs around $150 million.
Retail attention has spiked sharply relative to its own history. The Wikipedia and ORTEX page-view signal carried a z-score of 4.3 as of September 23, reflecting unusually elevated attention against the prior 90 days. That is colour rather than a directional indicator, but elevated retail interest ahead of an earnings print, combined with a 21% short position, creates a setup worth noting even without drawing causal conclusions.
Among correlated peers, the sector-wide weakness has been broad. SRRK fell 11.1% on the week, ACRV dropped 10.6%, and DNLI lost 7.4%. VKTX at minus 10.8% is tracking the sector rather than diverging from it, which suggests the week's move has been driven by biotech-wide selling rather than a company-specific deterioration. On the institutional side, State Street added over 1.2 million shares in the quarter to September 30, a notable addition at a time when some passive-adjacent holders have been trimming. The activist register carries no 13D filer, and BlackRock's most recent 13G amendment showed its stake declining from 5.3% to 4.5% as of April 2025, though those figures are as last disclosed and may not reflect current positioning.
With earnings on October 21, the question the data is framing is whether the short book, now heavily loaded and with availability tightening fast, will choose to cover ahead of results or press the position into a print that has historically delivered negative surprises: the last two quarterly moves were minus 2.2% and minus 6.7% the following day. The pace at which availability continues to compress in the final two weeks before the report is the clearest near-term signal to watch.
See the live data behind this article on ORTEX.
Open VKTX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
